NO NEED TO DROP-SHIP VIALS
Prefilled Unit-Dose MVASITM Bevacizumab-awwb Syringes
MVASI™ Bevacizumab-awwb, which was approved by the FDA in 2017, is now available in the United States. It is a new biosimilar to Avastin® that is widely used off-label in ophthalmology. Compliance and convenience are now possible with Edge Pharma's unit dose MVASI™ Bevacizumab-awwb syringes.
According to the FDA, "a biosimilar is approved after rigorous evaluation and testing by the applicant." "Prescribers and patients should have no concerns about using these medications instead of reference products because biosimilars:
- Silicone-Free syringes
- Meet FDA’s rigorous standards for approval
- Are manufactured in FDA-licensed facilities
- Are tracked as part of post-market surveillance to ensure continued safety"
From: What is a Biosimilar? (FDA file)
Edge offers FDA compliant, prefilled ready-to-administer compounded MVASI™ Bevacizumab-awwb syringes for eye injection without the need to drop-ship vials. Simply register for an online ordering account, submit the appropriate licenses, and start ordering.
No Minimum Ordering Requirements for MVASI™ syringes.
MVASI™ Bevacizumab-awwb Ophthalmic Injection
Concentration = 1.25 mg / 0.05 mL
MVASI™ Syringe Volume = 0.13 mL in a silicone-free syringe
MVASI™ Bevacizumab-awwb Syringe Features
- Silicone-Free syringes
- Meet new FDA requirements for subvisible particle testing
- No vial drop-shipping required. Simply log in and order.
- No contracts required and no minimum orders. Order as few as one syringe.
- Volume discounts and contracted pricing available. Call or email to inquire.
- Every batch of compounded MVASI™ syringes from Edge Pharma undergoes rigorous sterility, potency, endotoxin, visual inspection, and subvisible particle analysis before release.
1. According to the American Academy of Ophthalmology:
"Avastin® is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases.
Avastin® is the brand name for the drug, which is called bevacizumab. It blocks the growth of abnormal blood vessels in the back of the eye. Those blood vessels can leak and affect vision, causing vision loss from wet AMD and diabetic eye disease.
Avastin® is one of several anti-VEGF treatments that are injected into the eye.
Avastin® was first approved by the Food and Drug Administration (FDA) to treat different types of cancer. Its use to treat eye disease is considered an “off-label” use. The FDA allows “off label” drug use if doctors are well informed about the product and studies prove the drug is helpful."
"Bevacizumab (Avastin) is widely used off-label for treating neovascular ophthalmic diseases. Approval of the biosimilar [MVASI™], which will carry the generic name bevacizumab-awwb, was based on evidence from 2 comparative clinical trials as well as extensive structural and functional characterization."
2. Specialty Guideline Management -- AVASTIN (bevacizumab), MVASI (bevacizumab-awwb)
"The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy."
Section B.7.b: "Neovascular (wet) age-related macular degeneration (AMD)""
3. Clinical Policy: Bevacizumab (Avastin, Mvasi)
"It is the policy of health plans affiliated with Centene Corporation® that Avastin and Mvasi are medically necessary when the following criteria are met."
Section I.C.1.a: "Neovascular (wet) age-related macular degeneration"
4. According to the Blue Cross Blue Shield of Western New York website: "Drug Therapy Guidelines: Bevacizumab (Avastin® [bevacizumab], Mvasi® [bevacizumab-awwb])"
"Coverage of Avastin or Mvasi is also available for the following ophthalmic indications:"
- "Neovascular (wet) Age-related macular degeneration (AMD)"
- "Diabetic Macular Edema (DME)"
5. UnitedHealthcare Network Bulletin August 2019: Oncology Medication Clinical Coverage
"Policy update Oct. 1, 2019. The policy will be updated to include preferred product coverage criteria for Avastin® (bevacizumab) and Herceptin® (trastuzumab). Preferred product language will be added as follows:"
- "Use of Mvasi (bevacizumab-awwb) prior to the use of Avastin and other bevacizumab biosimilar products."
Register To Order Online
We are currently licensed to sell to all US states except Alabama and Virginia. Please fill the Form below to create an account. Medical, DEA, or hospital pharmacy licenses are required to order prefilled MVASI™ Bevacizumab syringes.
Create an account to orderLog-In if you have an account